newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration